Mark Lackner Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading activity

Mark Lackner is Chief Scientific Officer of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 512,856 shares of ZNTL, which is worth approximately $1.19 Million. The most recent transaction as insider was on Feb 03, 2025, when has been sold 14,368 shares (Common Stock) at a price of $1.71 per share, resulting in proceeds of $24,569. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 513K

162.02% 3M change

162.02% 12M change

Total Value Held $1.19 Million

Mark Lackner Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 03 2025	SELL Open market or private sale	$24,569 $1.71 p/Share	14,368 Reduced 2.73%	512,856 Common Stock
Feb 03 2025	BUY Grant, award, or other acquisition	-	335,907 Added 38.92%	527,224 Common Stock
Jan 02 2025	SELL Open market or private sale	$13,762 $3.12 p/Share	4,411 Reduced 2.25%	191,317 Common Stock
Feb 02 2024	SELL Open market or private sale	$18,290 $11.54 p/Share	1,585 Reduced 0.8%	195,728 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	141,000 Added 41.68%	197,313 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	40,000 Added 41.53%	56,313 Common Stock

Also insider at

IDYA

IDEAYA Biosciences, Inc. Healthcare

SVP, Head of Biology

Mark Lackner

Chief Scientific Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ZNTL shares.

Notify only if

Value

Insider Trading

Get notified when an Zentalis Pharmaceuticals, Inc. insider buys or sells ZNTL shares.

Notify only if

Operation

Value

Type

News

Receive news related to Zentalis Pharmaceuticals, Inc.

Track Activities on ZNTL

Account